EPO and Parkinson disease: Considering that the new CIM formulation of NeuroEPO constitutes an additional benefit over other variants of EPO for the treatment of neurodegenerative conditions, the corresponding Cuban regulatory entity announced the approval to initiate clinical trials in the initial stages of AD and PD.